Molecular Templates, Inc ( MTEM ) shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. 

The Details:

Molecular Templates ( MTEM ) said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed.

“We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need,” said CEO Eric Poma. 

“The long-lasting partial responses were in patients with low PD-L1 expression and showed concomitant increases in cytokines associated with T-cell activation and tumor microenvironment remodeling not seen with other checkpoint therapies. We believe the novel mechanism of action of MT-6402 may allow for durable, T-cell-mediated, monotherapy activity in patients who have progressed on checkpoint therapy," added Poma. 

Molecular Templates ( MTEM ) shares are moving on heavy trading volume Tuesday. According to data from Benzinga Pro, more than 1.47 million shares have been traded in the session, compared to the stock’s 100-day average of less than 27,000 shares.

Related News: What’s Going On With SoFi Technologies Stock?

Is MTEM A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Molecular Templates ( MTEM )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Molecular Templates ( MTEM ) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 110.75%, you'll need to buy a share of Lufax Holding by the June 4. Once done, you can expect to receive a nominal payout of $2.37 on June 8.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Molecular Templates ( MTEM ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

MTEM Price Action: According to Benzinga Pro, Molecular Templates ( MTEM ) shares are down 4.1% at $1.90 at the time of publication Tuesday.

Image: PublicDomainPictures from Pixabay